Ascendis Pharma Gets FDA Letter Noting Deficiencies in TransCon PTH's New Drug App
By Chris Wack Ascendis Pharma A/S said Monday that the U.S. Food & Drug Administration has found deficiencies in the company's new drug application for TransCon PTH, its candidate for the... | April 3, 2023
Source: marketscreener.com